1. Considerations for the Forced Expiratory Volume in 1 Second‐Based Comparative Clinical Endpoint Bioequivalence Studies for Orally Inhaled Drug Products
- Author
-
Jieon Lee, Kairui Feng, Denise S. Conti, Ross Walenga, Michael Wientjes, Hezhen Wang, Bryan Newman, Liangfeng Han, Sneha Dhapare, Elizabeth Bielski, Andrew Babiskin, Fang Wu, Mark Donnelly, Myong‐Jin Kim, Wenlei Jiang, Markham C. Luke, Lanyan Fang, and Liang Zhao
- Subjects
Pharmacology ,Therapeutic Equivalency ,Pharmaceutical Preparations ,United States Food and Drug Administration ,Forced Expiratory Volume ,Humans ,Drugs, Generic ,Pharmacology (medical) ,United States - Abstract
Herein, we present the US Food and Drug Administration (FDA) Office of Research and Standards' current thinking, challenges, and opportunities for comparative clinical endpoint bioequivalence (BE) studies of orally inhaled drug products (OIDPs). Given the product-associated complexities of OIDPs, the FDA currently uses an aggregate weight-of-evidence approach to demonstrate that a generic OIDP is bioequivalent to its reference listed drug. The approach utilizes comparative clinical endpoint BE or pharmacodynamic BE studies, pharmacokinetic BE studies, and in vitro BE studies to demonstrate equivalence, in addition to formulation sameness and device similarity. For the comparative clinical endpoint BE studies, metrics based on forced expiratory volume in the first second (FEV
- Published
- 2022
- Full Text
- View/download PDF